


**Product Name** : TQ-B3139  
**Cat. No.** : PC-49613  
**CAS No.** : 1621519-26-3  
**Molecular Formula** : C<sub>24</sub>H<sub>26</sub>Cl<sub>2</sub>FN<sub>5</sub>O<sub>2</sub>  
**Molecular Weight** : 506.40  
**Target** : Anaplastic Lymphoma Kinase (ALK)  
**Solubility** : 10 mM in DMSO



## Biological Activity

TQ-B3139 (Envonalkib, CT-711) is a potent inhibitor of **ALK** and **c-Met** kinases with IC<sub>50</sub> of 14.3 and 12.5 nM in cell-free assays, respectively.

TQ-B3139 (CT-711) inhibits ALK signaling pathway and induces G1 arrest and apoptosis.

TQ-B3139 (CT-711) is an ALK inhibitor with improved ALK inhibitory activity compared with crizotinib.

TQ-B3139 (CT-711) is preferentially efficacious against cells expressing EML4-ALK (NCI-H3122, NCI-H2228), NPM1-ALK (SU-DHL-1) and ALK activating F1174L point mutation (SK-N-SH) with IC<sub>50</sub> of 15-500 nM, but not ALK wild-type cells (NCI-H460, HCC827).

TQ-B3139 (CT-711) inhibits c-Met and overcomes resistance conferred by c-Met activation.

TQ-B3139 (CT-711) at a dose of 25 mg/kg inhibits the growth of ALK-driven tumors in vivo, exhibits significantly superiority to crizotinib against 32D harboring EML4-ALK L1196M and EML4-ALK C1156Y mutations.

Envonalkib is a potent, selective, and orally active inhibitor of ALK with IC<sub>50</sub> of 1.96 nM, 35.1 nM, and 61.3 nM for WT and mutated L1196M and G1269S-ALK, respectively.

Envonalkib (12.5-25 mg/kg; p.o. once daily for 14 days) inhibits the growth of human non-small cell lung cancer NCI-H2228 nude mice xenografts.

## References

Yuxiang Ma, et al. *Eur J Cancer*. 2022 Sep;173:238-249.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com